NEW YORK (GenomeWeb) – Startup PreCyte has received a two-year grant worth nearly $2 million from the National Institutes of Health to validate and optimize a technology that uses cultured cells to detect blood-based biomarkers for Alzheimer's disease.

With the Direct-to-Phase II Small Business Innovation Research grant, PreCyte aims to test the so-called Indicator Cell Assay Platform, or ICAP, in hundreds of blood samples from presymptomatic and early-stage Alzheimer's disease patients, as well as normal controls.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Nov
14
Sponsored by
PerkinElmer

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.